MedTrace Logo

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00004052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-06-25

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

Conditions

Interventions

BIOLOGICAL

QS21

BIOLOGICAL

bcr-abl peptide vaccine

Sponsors & Collaborators

Principal Investigators

  • Kathleen Cathcart, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004052 on ClinicalTrials.gov